登录新浪财经APP 搜索【信披】查看更多考评等级 调研基本情况 2026年1月28日15:00-16:00，天津九安医疗电子股份有限公司（以下简称"九安医疗"）通过电话会议方 式举办投资者线上交流会，接待了农银汇理、南方基金、大成基金、博时基金、前海开源、新华基金、 招商基金、光大保德信等8家机构。公司董事会秘书邬彤出席会议，就产品研发、糖尿病诊疗照 护"O+O"新模式、AIoT糖尿病家庭医助项目、科创投资及股东回报规划等事项与机构投资者进行沟 通。 核心议题解读 IVD产品进展：四联检试剂盒美国上市，智能助听器研发中 在产品研发方面，九安医疗介绍，IVD产品领域的iHealth四联检试剂盒已于2025年12月获得美国FDA 510(k)上市前通知，目前已在CVS开始销售，同时可通过亚马逊线上渠道订购。亚马逊平台显示，该产 品两人份售价29.99美元，四人份售价49.99美元（预售结束后定价54.99美元）。公司表示，该产品拓展 了试剂盒类产品的可检测病毒类别，有助于满足美国市场呼吸道病毒筛查多元化需求，提升核心竞争 力。值得注意的是，510(k)属于常规上市许可，不受EUA终止影响，可在美持续销售。 此外， ...

Core Viewpoint - Aojing Medical (688613.SH) forecasts a net profit attributable to shareholders of approximately 13.53 million yuan for the year 2025, representing an increase of about 26.19 million yuan compared to the previous year, indicating a turnaround from loss to profit [1] Group 1: Performance Forecast - The company expects to achieve a net profit of approximately 13.53 million yuan for 2025 [1] - This represents an increase of about 26.19 million yuan compared to the same period last year [1] - The anticipated performance marks a turnaround from previous losses [1] Group 2: Reasons for Performance Change - The increase in performance is primarily attributed to the orthopedic artificial bone procurement, which has provided opportunities for continued clinical usage and market share expansion [1] - The company has strengthened its production guarantee system to ensure stable fulfillment of the increased demand resulting from procurement [1] Group 3: Marketing Strategy - The company continues to deepen its regional market strategy through refined management and precise marketing tactics [1] - There is a consistent expansion of the sales network, contributing to robust growth in annual operating revenue [1] - This strategy further consolidates the company's leading position in the segmented market [1]

Core Viewpoint - Aojing Medical (688613.SH) forecasts a net profit attributable to shareholders of approximately 13.53 million yuan for the year 2025, representing an increase of about 26.19 million yuan compared to the previous year, indicating a turnaround from loss to profit [1] Group 1: Performance Forecast - The company expects to achieve a net profit of approximately 13.53 million yuan in 2025 [1] - This represents an increase of about 26.19 million yuan compared to the same period last year [1] - The anticipated performance marks a significant turnaround from previous losses [1] Group 2: Reasons for Performance Change - The main reason for the performance change is the increase in clinical usage of orthopedic artificial bone due to centralized procurement, which provides opportunities for continued market share expansion [1] - The company has strengthened its production assurance system to meet the increased demand resulting from centralized procurement [1] Group 3: Marketing and Sales Strategy - The company continues to deepen its regional market strategy through refined management and targeted marketing strategies [1] - There is a steady growth trend in annual operating revenue, further consolidating the company's leading position in the niche market [1]

证券之星消息，截至2026年1月28日收盘，天臣医疗(688013)报收于43.42元，下跌0.37%，换手率 1.69%，成交量1.37万手，成交额5955.36万元。 1月28日的资金流向数据方面，主力资金净流出519.63万元，占总成交额8.73%，游资资金净流入51.87 万元，占总成交额0.87%，散户资金净流入467.76万元，占总成交额7.85%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 天臣医疗2025年三季报显示，前三季度公司主营收入2.44亿元，同比上升20.66%；归母净利润7194.58 万元，同比上升68.29%；扣非净利润6620.23万元，同比上升71.85%；其中2025年第三季度，公司单季 度主营收入8766.31万元，同比上升26.4%；单季度归母净利润2373.42万元，同比上升70.74%；单季度 扣非净利润2191.58万元，同比上升72.61%；负债率11.3%，投资收益255.6万元，财务费用-1087.03万 元，毛利率63.22%。天臣医疗（688013）主营业务：专注于高端外科手术吻合器研发创新和生产销 售。 该股最近90天内共有1家机构 ...

Group 1 - The core business of cardiovascular interventional products has shown steady revenue growth, while the inventory clearance in the retail channel of the pharmaceutical segment is nearly complete, leading to double-digit revenue growth for Lepu Medical [1] - Lepu Medical forecasts a net profit attributable to shareholders of 800 million to 1.2 billion yuan for 2025, representing a year-on-year growth of 223.97% to 385.95% [3] - The net profit after deducting non-recurring gains and losses is also projected to be between 800 million to 1.2 billion yuan, with a year-on-year increase of 261.29% to 441.93% [3]

Core Viewpoint - The financial performance of Xinmai Medical (688016) shows mixed results, with revenue growth but a significant decline in net profit, indicating potential challenges ahead for the company [2]. Financial Performance - For the first three quarters of 2025, Xinmai Medical reported a total revenue of 1.015 billion yuan, an increase of 4.66% year-on-year [2]. - The net profit attributable to shareholders decreased by 22.46% to 429 million yuan [2]. - The net profit after deducting non-recurring items fell by 25.8% to 372 million yuan [2]. - In Q3 2025, the company achieved a quarterly revenue of 300 million yuan, a substantial increase of 64.68% year-on-year [2]. - The quarterly net profit attributable to shareholders was 114 million yuan, down 23.63% year-on-year [2]. - The quarterly net profit after deducting non-recurring items was 102 million yuan, a decrease of 11.84% [2]. - The company's debt ratio stands at 15.85%, with investment income of 11.6033 million yuan and financial expenses of -7.8584 million yuan [2]. - The gross profit margin is reported at 70.4% [2]. Market Activity - As of January 28, 2026, Xinmai Medical's stock closed at 94.0 yuan, down 1.67% with a turnover rate of 1.29% and a trading volume of 15,900 hands, amounting to a transaction value of 150 million yuan [1]. - On January 28, the net outflow of main funds was 10.3432 million yuan, accounting for 6.89% of the total transaction value, while retail funds saw a net outflow of 2.9068 million yuan, making up 1.94% [1]. - Conversely, speculative funds experienced a net inflow of 13.25 million yuan, representing 8.82% of the total transaction value [1]. Analyst Ratings - In the last 90 days, seven institutions have provided ratings for Xinmai Medical, with six giving a "buy" rating and one an "increase" rating [2]. - The average target price set by institutions over the past 90 days is 1.3603 billion yuan [2].

Group 1 - The core viewpoint of the article is that Aojing Medical is expected to achieve a net profit of approximately 13.53 million yuan for the year 2025, marking an increase of about 26.19 million yuan compared to the previous year, thus turning a profit [1] - The main reason for the performance change is the opportunity provided by the centralized procurement of orthopedic artificial bones, which has allowed the company to increase clinical usage and further expand its market share [1] - The company has strengthened its production guarantee system to ensure stable supply to meet the increased demand from centralized procurement [1] Group 2 - In terms of marketing strategy, the company continues to deepen its regional market strategy through refined management and precise marketing tactics, thereby expanding its sales network [1] - The company's annual operating revenue shows a steady growth trend, further consolidating its leading position in the niche market [1]

智通财经APP讯，三诺生物(300298.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润 8500万元至1.28亿元，同比下降60.92%至73.95%;扣除非经常性损益后的净利润4500万元至6750万元。 ...

Core Viewpoint - The rehabilitation medical industry in China is undergoing significant transformation driven by technological innovation and a focus on clinical needs, as evidenced by the experiences of young entrepreneurs like Wang Daoyu [1][10]. Group 1: Industry Challenges - The rehabilitation medical industry faced initial challenges such as weak supply and heavy reliance on imports, particularly for high-end rehabilitation robots, which were scarce and expensive [2]. - The core contradiction in the industry was the imbalance between patient rehabilitation needs and the insufficient supply of quality rehabilitation resources, especially products tailored to local clinical scenarios [2]. - The industry is characterized by long development cycles and high investment requirements, with product development taking over four years from research to market launch [4][5]. Group 2: Technological Innovation - The focus of technological innovation has shifted from complex structures to addressing clinical needs, emphasizing the importance of practical solutions for patients [6]. - Innovations include the application of eye-tracking technology for rehabilitation training and AI integration for dynamic adjustment of rehabilitation plans based on patient data [6]. - Full-stack self-research is identified as a key direction for technological innovation, aiming to reduce costs and enhance adaptability through proprietary technology [6]. Group 3: Industry Standards and Collaboration - The establishment of industry standards is crucial for the healthy development of the rehabilitation medical field, as early practitioners played a significant role in drafting relevant standards [7]. - Collaboration among industry, academia, and research institutions is essential for aligning technology development with clinical needs and accelerating the translation of technological achievements [7]. Group 4: Future Trends - The rehabilitation medical industry is expected to extend from institutional settings to home care, with a growing demand for practical home rehabilitation products [8]. - Achieving equal access to rehabilitation services across different regions is a key challenge, with the potential for "robot + IoT" models to provide remote rehabilitation services [9]. - The internationalization of Chinese rehabilitation medical technology is seen as viable, with industry alliances suggested as a means to enhance global competitiveness and market access [9]. Group 5: Entrepreneurial Insights - Patience and adherence to core values are emphasized as essential qualities for those entering the rehabilitation medical field, highlighting the importance of a supportive innovation ecosystem [10]. - The rich innovation resources and supportive policies in regions like Shanghai provide a solid foundation for the development of the rehabilitation medical industry [10].

（文章来源：证券日报） 证券日报网讯 1月28日，赛科希德发布公告称，公司2025年实现营业收入263，667，956.92元，同比下 降13.80%；归属于母公司所有者的净利润87，143，189.53元，同比下降22.88%。 ...